Stockscreener 앱 받기
3.98
4.19%
0.16
Amylyx Pharmaceuticals Inc 주식(AMLX)의 최신 뉴스
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Investors to Learn More About the Investigation - markets.businessinsider.com
Q1 Earnings Forecast for AMLX Issued By Leerink Partnrs - Defense World
Is Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) the Best Biotech Penny Stock to Buy According to Hedge Funds? - Insider Monkey
Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Stockholders to Connect - markets.businessinsider.com
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Purchased by American Century Companies Inc. - Defense World
American Century Companies Inc. Increases Stock Holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - The AM Reporter
Wellington Management Group LLP Acquires Shares of 209,708 Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - The AM Reporter
Wellington Management Group LLP Makes New $793,000 Investment in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World
Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - markets.businessinsider.com
Amylyx upgraded at Mizuho on potential of lead asset - MSN
First subject dosed in Amylyx’s Phase I trial of ALS therapy - MSN
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Stockholders to Learn More About the Investigation - markets.businessinsider.com
Amylyx Pharmaceuticals Announces First Participant Dosed in Phase 1, Multiple Ascending Dose LUMINA Trial of AMX0114 in People Living with Amyotrophic Lateral Sclerosis - BioSpace
Amylyx Pharma Announces First Participant Dosed In Phase 1, Multiple Ascending Dose Lumina Trial Of Amx0114 In People Living With Amyotrophic Lateral Sclerosis - marketscreener.com
Breakthrough ALS Treatment Enters Human Trials: Amylyx Targets New Disease Mechanism - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Investors to Inquire about Securities Investigation - markets.businessinsider.com
Is Now The Time To Buy Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) Stock? - stocksregister.com
Amylyx Pharmaceuticals (NASDAQ:AMLX) Rating Increased to Outperform at Mizuho - Defense World
Mizuho Upgrades Amylyx Pharmaceuticals (AMLX) - Nasdaq
Amylyx stock upgraded at Mizuho on lead asset (AMLX:NASDAQ) - Seeking Alpha
Mizuho lifts Amylyx stock rating, doubles price target to $7 - Investing.com
Mizuho lifts Amylyx stock rating, doubles price target to $7 By Investing.com - Investing.com UK
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Reach Out - markets.businessinsider.com
Investors in Amylyx Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your RightsAMLX - ACCESS Newswire
Don't Ignore The Insider Selling In Amylyx Pharmaceuticals - simplywall.st
Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - markets.businessinsider.com
Amylyx Pharmaceuticals co-CEO Justin Klee sells $74,454 in stock - Investing.com Australia
Optimistic Investors Push Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Up 26% But Growth Is Lacking - simplywall.st
Amylyx Pharmaceuticals Executives Unload Massive Stock Shares! - TipRanks
Amylyx Pharmaceuticals co-CEO Justin Klee sells $74,454 in stock By Investing.com - Investing.com South Africa
Amylyx Pharmaceuticals chief medical officer sells $43,082 in stock By Investing.com - Investing.com South Africa
Amylyx Pharmaceuticals chief medical officer sells $43,082 in stock - Investing.com
Amylyx Pharmaceuticals chief legal officer sells $31,954 in stock By Investing.com - Investing.com South Africa
Amylyx Pharmaceuticals’ co-CEO Joshua Cohen sells $74,482 in stock By Investing.com - Investing.com South Africa
Amylyx Pharmaceuticals Executives Sell Shares to Cover Tax Obligations - TradingView
Amylyx Pharmaceuticals chief legal officer sells $31,954 in stock - Investing.com India
Amylyx Pharmaceuticals’ co-CEO Joshua Cohen sells $74,482 in stock - Investing.com
Amylyx Pharmaceuticals Executives Sell Shares for Tax Obligations - TradingView
Amylyx Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference - BioSpace
Amylyx Pharmaceuticals Set to Reveal Latest Corporate Strategy at Major Healthcare Conference - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Shareholders to Inquire about Securities Investigation - markets.businessinsider.com
Does Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) Still Look Hot This Week? - stocksregister.com
Charles Schwab Investment Management Inc. Lowers Position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Shareholders to Connect - markets.businessinsider.com
Amylyx Pharmaceuticals, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More InformationAMLX - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Shareholders to Reach Out - Markets Insider
Is Amylyx Pharmaceuticals (AMLX) The Hot Biotech Stock Under $5? - Insider Monkey
Amylyx Pharmaceuticals director Bernhardt Zeiher buys $37,005 in stock By Investing.com - Investing.com South Africa
Amylyx Pharmaceuticals director Bernhardt Zeiher buys $37,005 in stock - Investing.com India
2.51%
자본화:
|
볼륨(24시간):